Transaction and Project Screening

The decision to move forward with a biotechnology transaction or initiative involves a commitment of limited resources. Engage Triaj as your independent expert to provide early screening of your biotechnology transactions and initiatives before you commit your resources. Triaj helps you to choose transactions and projects that have the highest likelihood of future success.

Despite the number of investment and business development opportunities in biotechnology being at an all-time high, there is a global shortage of scientific expertise to evaluate transactions, review technical capabilities and manage complex information. As a result, many investment professionals, legal practitioners, biotechnology, pharmaceutical companies and governmental agencies have been forced to rely upon scientific generalists with limited expertise in critical areas. This increases the risk of sub-optimal decision-making, and can result in significant opportunity cost, lower internal rates of return, and governance issues.

Tight deadlines and limited information heightens the risk profile of many biotechnology transactions. These risks are typically greatest at the outset of a project. Triaj offers an initial screening review and project review service when it counts - before valuable time and resources are wasted.

Triaj's initial scientific screening is an impartial fact-driven process that increases your ability to identify and exploit new opportunities. Triaj's initial screening review services are tailored to meet the needs of the venture capital, investment banking and legal communities, as well as corporate development departments of biotechnology and pharmaceutical companies, and government agencies. We are equipped to screen any size or type of transaction, including venture capital investments, initial public offerings, mergers, acquisitions and dispositions, joint ventures and product development.

Triaj's biotechnology professionals are recognized international leaders in their field, and include experts in genetics, genomics, proteomics, molecular biology, genetic statistics, clinical epidemiology, genetic epidemiology, biostatistics, bioinfomatics, diagnostics, therapeutics, and gene mapping. Triaj's professional staff has a wealth of experience in all aspects of the biotechnology industry, providing unique and unparalleled project expertise.

Triaj's initial scientific screening can be an invaluable tool that allows you to increase the return on your time and resources. Let Triaj provide you with the scientific expertise critical to the success of your enterprise.

Profit from Triaj's experience.

Scientific review screening for:

• Venture capitalists, investment banks, law firms, biotech and pharmaceutical companies, governmental agencies, and other institutions
• Mergers and acquisitions, IPOs, roll-ups, joint ventures, partnerships, divestitures, management buyouts, product development projects, funding contracts, and other special projects.
• Initial feasibility review, market opportunity and competitor analysis, review of human capital and physical resource requirements, analysis of the project time lines, milestones, and budget, and other important data sets.

---

Back to Services